Is semaglutide safe during pregnancy or breastfeeding? Learn the latest safety insights and how to plan fertility with guidance from licensed medical providers.
Semaglutide is a GLP-1 receptor agonist approved by the FDA for the treatment of type 2 diabetes and chronic weight management under brand names such as Wegovy®, Ozempic®, and Rybelsus®. As its use expands for metabolic health support, many individuals have questions about semaglutide and pregnancy, particularly its safety during fertility planning, active pregnancy, and breastfeeding.
This article outlines current scientific understanding and regulatory guidance to help patients make informed decisions with their healthcare providers.
Semaglutide is not approved as a fertility treatment. However, in individuals with overweight or obesity, it may improve insulin sensitivity and support weight loss, helping address conditions like PCOS. These changes may support ovulation and hormonal balance.
While early evidence suggests potential fertility benefits, semaglutide should not be taken during an active fertility cycle or pregnancy. Clinical decisions must be licensed medical provider-guided.
Semaglutide is not approved for use during pregnancy. Preclinical data show risks such as:
Due to its long half-life, patients are advised to discontinue semaglutide at least two months before attempting conception.
There is limited human data on semaglutide and lactation. One study found the drug was not detected in breast milk samples, suggesting a low risk of infant exposure.
However, due to the lack of long-term safety data, alternatives like metformin or insulin may be recommended for managing metabolic conditions while breastfeeding.
Individuals who are pregnant, planning to become pregnant, or breastfeeding should consult with a licensed healthcare professional before starting or continuing treatment with semaglutide. A medical provider can help evaluate the risks and benefits of treatment and provide guidance tailored to your reproductive health goals.
Semaglutide comes in:
Consult your licensed healthcare provider to determine the most appropriate format, particularly during reproductive planning.
Semaglutide may be effective for metabolic support, but should be used with caution around pregnancy and breastfeeding. Its use must be guided by a licensed medical provider, and patients should discontinue it before conception efforts.
The information provided in this article is for general educational purposes only and is not intended as medical advice. Semaglutide is not approved for use during pregnancy, and its safety has not been established for individuals who are pregnant, planning to become pregnant, or breastfeeding. Treatment decisions should always be made in consultation with a licensed healthcare provider who can evaluate the potential risks and benefits based on your individual health needs. Eden does not practice medicine or prescribe treatments; we connect patients with licensed medical professionals who provide personalized care.
Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.
De Athayde De Hollanda Morais, B. A., Prizão, V. M., De Moura De Souza, M., Mendes, B. X., Defante, M. L. R., Martins, O. C., & Rodrigues, A. M. (2024). The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: A meta-analysis of randomized controlled trials. Journal of Diabetes and Its Complications, 38(10), 108834. https://doi.org/10.1016/j.jdiacomp.2024.108834
Jones, W. (2024, July 16). Semaglutide and breastfeeding – breastfeeding and medication. https://breastfeeding-and-medication.co.uk/fact-sheet/semaglutide-and-breastfeeding
National Institute of Child Health and Human Development. (2024, December 15). Semaglutide. Drugs and Lactation Database (LactMed®) - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK500980/
Organization of Teratology Information Specialists (OTIS). (2023, March 1). Semaglutide. MotherToBaby | Fact Sheets - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK600385/
Skov, K., Mandic, I. N., & Nyborg, K. M. (2023). Semaglutide and pregnancy. International Journal of Gynecology & Obstetrics, 163(2), 699–700. https://doi.org/10.1002/ijgo.15092
